Notice2025-10920
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 16, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 114 (Monday, June 16, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 114 (Monday, June 16, 2025)]
[Notices]
[Page 25345]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-10920]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by contacting Chris Kornak at 240-
627-3705 or at <a href="/cdn-cgi/l/email-protection#92f1fae0fbe1bcf9fde0fcf3f9d2fcfbfabcf5fde4"><span class="__cf_email__" data-cfemail="53303b213a207d383c213d3238133d3a3b7d343c25">[email protected]</span></a>. A signed Confidential Disclosure
Agreement will be required to receive copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
A Novel Strategy To Produce 6-cys Proteins Based on Pfs230D1 Domain
Fusions
Description of Technology
The Plasmodium parasite has a complex lifecycle during human
infection and in the mosquito vector. Most advanced malaria vaccine
candidates can confer only partial, short-term protection in malaria-
endemic areas. A means of breaking the transmission of malaria to
subsequent individuals could prevent a significant amount of human
disease.
The primary embodiments of this technology are novel compositions
of matter that produce enhanced transmission-blocking responses over
current transmission blocking vaccines:
<bullet> The inventors designed fusion protein sequences
incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with
additional Plasmodium 6-cys domains downstream.
<bullet> The artificial immunogens retained structured transmission
blocking epitopes.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications: This technology could be used
alone or in combination with existing malaria vaccines.
Competitive Advantages:
<bullet> The immunogens were used in small animal vaccination
studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3
fusions prompted greater functional serum activity compared to Pfs230D1
alone.
<bullet> Pfs230D1 or its ortholog Pvs230D1 enabled expression of
other down stream domains of Pvs230 or Pv48/45D3 another malaria
species that causes human disease.
Developmental Stage:
<bullet> Pre-clinical
Inventors: Dr. Patrick Duffy (NIAID) and Dr. Jonathan Renn (NIAID).
Intellectual Property: HHS Reference No. E-086-2023; Provisional
Patent Application No.: 63/617,717, filed on January 4, 2024, and PCT
Patent Application No. PCT/US2025/010325, filed on January 3, 2025.
Licensing Contact: To license this technology, please contact Chris
Kornak 240-627-3705 or <a href="/cdn-cgi/l/email-protection#781b100a110b5613170a16191338161110561f170e"><span class="__cf_email__" data-cfemail="4f2c273d263c6124203d212e240f21262761282039">[email protected]</span></a>, and reference E-086-2023.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Chris Kornak 240-627-3705 or
<a href="/cdn-cgi/l/email-protection#dab9b2a8b3a9f4b1b5a8b4bbb19ab4b3b2f4bdb5ac"><span class="__cf_email__" data-cfemail="4f2c273d263c6124203d212e240f21262761282039">[email protected]</span></a>, and reference E-086-2023.
Dated: June 9, 2025.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2025-10920 Filed 6-13-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 16, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.